z-logo
Premium
Canine mammary carcinomas: influence of histological grade, vascular invasion, proliferation, microvessel density and VEGFR2 expression on lymph node status and survival time
Author(s) -
Diessler M. E.,
Castellano M. C.,
Portiansky E. L.,
Burns S.,
Idiart J. R.
Publication year - 2017
Publication title -
veterinary and comparative oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.864
H-Index - 34
eISSN - 1476-5829
pISSN - 1476-5810
DOI - 10.1111/vco.12189
Subject(s) - proliferating cell nuclear antigen , pathology , lymph node , microvessel , lymph , medicine , vascular endothelial growth factor , kinase insert domain receptor , immunohistochemistry , biology , vascular endothelial growth factor a , vegf receptors
Spontaneous invasive non‐inflammatory canine mammary carcinomas ( CMC ) and their regional lymph nodes ( LN ) were analysed ( n = 136). Histological grade ( HG ) and vascular invasion ( VI ) in the tumours and lymph node status were recorded. Proliferation index ( PI ), microvessel density ( MVD ) and vascular endothelial growth factor receptor 2 ( VEGFR2 ) expression were estimated using anti‐proliferating cell nuclear antigen ( PCNA ), anti‐von Willebrand factor and anti‐Flk‐1, respectively. Eighteen months follow‐up was performed (34 bitches). Tumours of different grades showed differences regarding PI , Flk‐1/integrated optical density (Flk‐1/ IOD ) and MVD . Every feature showed significant association with LN status through bivariate analyses. From multivariate analyses, VI and Flk‐1/ IOD were selected to predict LN status. Data revealed that the probability of a CMC ‐bearing bitch to remain alive at 1, 4, 5 and 14–18 months was 0.91, 0.87, 0.81 and 0.77, respectively. Besides LN status, VI was the only feature positively correlated with survival time, although a trend to shorter survival of animal patients bearing high expressing VEGFR2 CMC was noted.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here